Načítá se...
Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer
OBJECTIVE: Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. The aim of this study was to investigate the efficacy of re-administration of the same TKI after failure of gefi...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Pioneer Bioscience Publishing Company
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3755689/ https://ncbi.nlm.nih.gov/pubmed/23991294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2013.07.28 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|